ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

World Journal of *Gastroenterology*

World J Gastroenterol 2017 September 14; 23(34): 6197-6370

Published by Baishideng Publishing Group Inc

World Journal of Gastroenterology

Contents

Weekly Volume 23 Number 34 September 14, 2017

NAME OF JOURNAL
World Journal of Gastroenterology

ISSN
ISSN 1007-9327 (print)
ISSN 2219-2840 (online)

LAUNCH DATE
October 1, 1995

FREQUENCY
Weekly

EDITORIAL OFFICE
Jin-Lei Wang, Director
Yuan Qi, Vice Director
Ze-Mao Gong, Vice Director
World Journal of Gastroenterology
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: editorialoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLISHER
Baishideng Publishing Group Inc
7901 Stoneridge Drive, Suite 501,
Pleasanton, CA 94588, USA
Telephone: +1-925-2238242
Fax: +1-925-2238243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

PUBLICATION DATE
September 14, 2017

INSTRUCTIONS TO AUTHORS
Full instructions are available online at http://www.wjgnet.com/bpg/gerinfo/204

ONLINE SUBMISSION
http://www.f6publishing.com

World Journal of Gastroenterology

Submit a Manuscript: http://www.f6publishing.com

World J Gastroenterol 2017 September 14; 23(34): 6197-6200

DOI: 10.3748/wjg.v23.i34.6197

ISSN 1007-9327 (print) ISSN 2219-2840 (online)

EDITORIAL

Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy

Konstantinos Papamichael, Adam S Cheifetz

Konstantinos Papamichael, Adam S Cheifetz, Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, United States

ORCID number: Konstantinos Papamichael (0000-0003-1497-0254); Adam S Cheifetz (0000-0002-6010-1896).

Author contributions: Papamichael K wrote the manuscript; Cheifetz AS contributed to the manuscript critical revision; all authors approved the final version of the article.

Conflict-of-interest statement: Papamichael K has nothing to disclose; Cheifetz AS has received consultancy fees from AbbVie, Janssen, Takeda, Ferring, AMAG, Miraca and Pfizer.

Manuscript source: Invited manuscript

Correspondence to: Konstantinos Papamichael, MD, PhD, FEBGH, Center for Inflammatory Bowel Diseases, Division of Gastroenterology, Beth-Israel Deaconess Medical Center, Harvard Medical School, 330 Brookline Ave., Boston, MA 02215, United States. kpapamic@bidmc.harvard.edu
Telephone: +1-617-6672802
Fax: +1-617-6675826

Received: July 28, 2017
Peer-review started: July 28, 2017
First decision: August 10, 2017
Revised: August 16, 2017
Accepted: September 5, 2017
Article in press: September 5, 2017

Published online: September 14, 2017

Abstract

Perianal fistulas can occur to up to one-third of patients with Crohn's disease (CD) leading to significant disabling disease and morbidity. Fistulising perianal CD treatment often necessitates a combined pharmacological and surgical approach. Anti-tumor necrosis factor (anti-TNF) therapy, particularly infliximab, has been shown to be very effective for both perianal and internal fistulising CD. Nevertheless, current data suggest that sustained remission and long-term complete fistula healing can be achieved in only 30% to 50% of patients. Moreover, these percentages refer mostly to clinical rather than deep remission, defined as endoscopic and radiologic remission, which is quickly emerging as the preferred goal of therapy. Unfortunately, the therapeutic options for perianal fistulising CD are still limited. As such, it would be of great value to be able to predict, and more importantly, prevent treatment failure in these patients by early and continued optimization of anti-TNF therapy. Similar to ulcerative colitis and luminal CD, recent data demonstrate that higher infliximab concentrations are associated with better clinical outcomes in patients with perianal fistulising CD. This suggests that therapeutic drug monitoring and a treat-to-trough therapeutic approach may emerge as the new standard of care for optimizing anti-TNF therapy in patients with perianal fistulising CD.

Key words: Inflammatory bowel disease; Infliximab; Adalimumab; Magnetic resonance imaging; Drug monitoring; Fistula healing

Core tip: Defining and predicting deep remission is important to guide the management of patients with perianal fistulizing Crohn's disease (CD). Deep remission, defined as complete fistula healing based on objective endoscopic and radiologic findings, should be the goal of care in the treatment of patients with perianal CD. Currently, anti-tumor necrosis factor (anti-TNF) are the standard of care for perianal CD, but long-term outcomes are disappointing. Data suggests that higher infliximab concentrations are associated with better clinical outcomes in patients with perianal fistulising CD and thus therapeutic drug monitoring may be a valid therapeutic strategy for optimizing anti-TNF therapy towards improved objective outcomes and deep remission.

Papamichael K, Cheifetz AS. Defining and predicting deep remission in patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor therapy. *World J Gastroenterol* 2017; 23(34): 6197-6200 Available from: URL: http://www.wjgnet.com/1007-9327/full/v23/i34/6197.htm DOI: http://dx.doi.org/10.3748/wjg.v23.i34.6197

INTRODUCTION

Perianal fistulas can develop to up to one-third of patients with Crohn's disease (CD) leading to disabling disease, morbidity, and a significant impairment in quality of life[1]. The treatment of fistulising perianal CD is not simple and often requires a multidisciplinary approach of both pharmacological and surgical therapy especially for complex perianal fistulae[2]. Anti-tumor necrosis factor (anti-TNF) therapy has revolutionized the treatment of both perianal and internal fistulising CD[3-18]. Nevertheless, therapeutic outcomes from randomised controlled trials (RCTs), post-hoc analyses of RCTs and real-life prospective or retrospective studies show that long-term remission can be achieved in only 30%-50% of patients (Table 1). Moreover, these percentages refer mostly to clinical remission, based on symptoms and physician global assessment (PGA), and not to objective endoscopic and/or radiological healing. At this time, the preferred goal of treatment should be deep remission, or the combination of clinical and the more objective measures, including radiologic and endoscopic healing. As therapeutic options for perianal fistulising CD are still limited it is very important to attempt to predict and subsequently prevent treatment failure in these patients. Preliminary data demonstrate that higher infliximab concentrations are associated with improved clinical outcomes in patients with perianal fistulising CD, suggesting that therapeutic drug monitoring (TDM) and a treat-to-trough approach is likely a valid therapeutic strategy for optimizing anti-TNF therapy in these patients[19,20].

Defining deep remission

Most studies typically use clinical remission, defined as absence of any draining fistulas based on PGA and patients' reports, as a therapeutic endpoint for perianal fistulising CD[3-18]. Nevertheless, deep remission, defined as mucosal and/or radiological healing of fistulas, is likely a more appropriate goal of therapy for perianal fistulising CD. T2-weighted magnetic resonance imaging (MRI) with fat-suppression is considered the gold-standard for fistula imaging and an MRI-based score is currently available for defining disease activity, although it is still not widely used in clinical practice[1]. Thomassin *et al*[11] have recently showed that deep remission, defined as a composite clinical (absence of any draining fistulas and self-reported drainage episodes by the patient at two successive evaluations), endoscopic (absence of ulcers in the anal canal) and radiological (absence of T2 hyperintensity and contrast enhancement on MRI) remission, was achieved in approximately one-third of patients with perianal fistulizing CD[11].

Predicting deep remission

As new drugs for the treatment of perianal fistulising CD are still awaited, it is important to be able to predict who will achieve deep remission and who will not respond adequately to typical anti-TNF dosing and will require early (and continued) optimization[1,2]. Although several variables have been associated with improved outcomes (Table 2), prediction of deep remission remains a challenge. Thomassin *et al*[11] have recently identified absence of rectal involvement on MRI (OR = 4.6; 95%CI: 1.03-20.5) as the only variable associated with deep remission in patients with perianal fistulizing CD[11]. Similar to ulcerative colitis and luminal CD[19-25], recent data demonstrate that higher infliximab concentrations are associated with better clinical outcomes in patients with perianal fistulising CD[26,27]. Regarding maintenance therapy Yarur *et al*[26] recently showed that infliximab trough concentrations $\geqslant$ 10.1 μg/mL are associated with fistula healing and based on quartile analyses proposed that physicians should aim for even higher concentrations (> 20.2 μg/mL) before giving up and moving on to alternative therapies with a different mechanism of action.

CONCLUSION

Deep remission defined as a composite clinical, endoscopic and radiological remission should really be considered the goal of therapy in patients with perianal fistulizing CD. TDM may be a valid therapeutic strategy for optimising anti-TNF therapy, improving therapeutic outcomes, and moving towards more personalized medical care.

Table 1 Long-term outcomes of patients with perianal fistulizing Crohn's disease on anti-tumor necrosis factor maintenance therapy

Type of anti-TNF therapy	*n*	Complex fistulas, %	Follow up, wk	Therapeutic outcome of interest	Therapeutic outcome, %	Ref.
IFX	68	75	52	Complete fistula closure & CDAI < 150	34	[4]
IFX	59	85	> 56	Complete fistula closure (PGA)	41	[5]
IFX	13	ND	95[1]	Reduction of fistulas number (MRI)	15	[5]
IFX	156	82	250[1]	At least 1 fistula closure	69	[6]
IFX	12	ND	156	Clinical remission (PGA)	33	[7]
IFX	12	ND	156	Radiological healing (MRI)	42	[7]
IFX	19	ND	52	Absence of draining fistulas (PGA)	53	[8]
IFX	26	69	255[2]	Complete fistula closure	42	[9]
IFX (RCT)	96	ND	54	Complete fistula closure	36	[10]
IFX/ADM	49	ND	160[2]	Deep remission (PGA, MRI, endoscopy)	33	[11]
IFX/ADM	49	ND	160[2]	Absence of draining fistulas (PGA)	53	[11]
IFX/ADM	20	ND	52	Absence of draining fistulas (PGA)	35	[12]
IFX/ADM	78	67	192[1]	Absence of drainage with seton removal	53	[13]
IFX/ADM	20	ND	78	Radiological healing (MRI)	30	[8]
ADM	7	ND	156	Absence of draining fistulas (PGA)	0	[7]
ADM	7	ND	156	Radiological healing (MRI)	14	[7]
ADM	7	ND	52	Absence of draining fistulas (PGA)	29	[8]
ADM	39	ND	52	Clinical remission (FDAI)	41	[14]
ADM	14	ND	52	Radiological healing (MRI)	43	[14]
ADM	53	ND	40	Complete fistula closure	41	[15]
ADM (RCT)	70	ND	56	Absence of draining fistulas (PGA)	33	[16]
ADM (post hoc)	70	ND	116	Absence of draining fistulas (PGA)	31	[17]
CZP (RCT)	28	ND	26	Complete fistula closure	36	[18]

[1]Median; [2]Mean. CDAI: Crohn's disease activity index; TNF: Tumor necrosis factor; ADM: Adalimumab; IFX: Infliximab; CZP: Certolizumab pegol; RCT: Randomized controlled trial; PGA: Physician global assessment; ND: Not defined; FDAI: Fistula drainage assessment index; MRI: Magnetic resonance imaging.

Table 2 Variables associated with improved therapeutic outcomes of anti-tumor necrosis factor maintenance therapy in patients with perianal fistulizing Crohn's disease

Variables	Ref.
Clinical or phenotypic	
Ileocolonic disease	[6]
Concomitant immunosuppressants	[6]
Duration of seton drainage (< 34 wk)	[6]
Duration of infliximab treatment (> 118 wk)	[6]
Number of infliximab infusions (> 19)	[6]
Absence of complex fistulas	[14]
Male gender	[26]
Absence of switch of anti-TNF therapy	[11]
Imaging	
Absence of persisting fistulas on MRI	[5]
Absence of collections at baseline on MRI	[5]
Absence of rectal wall involvement on MRI	[5]
Absence of single-branched fistulas on MRI	[5]
Absence of rectal involvement on MRI	[11]
Serologic	
Infliximab (maintenance) trough concentrations ⩾ 10.1 μg/mL	[26]
Endoscopic	
Absence of active proctitis	[11]

TNF: Tumor necrosis factor; MRI: Magnetic resonance imaging.

REFERENCES

1 **Gecse KB**, Sebastian S, Hertogh Gd, Yassin NA, Kotze PG, Reinisch W, Spinelli A, Koutroubakis IE, Katsanos KH, Hart A, van den Brink GR, Rogler G, Bemelman WA. Results of the Fifth Scientific Workshop of the ECCO [II]: Clinical Aspects of Perianal Fistulising Crohn's Disease-the Unmet Needs. *J Crohns Colitis* 2016; **10**: 758-765 [PMID: 26826183 DOI: 10.1093/ecco-jcc/jjw039]

2 **Gecse KB**, Bemelman W, Kamm MA, Stoker J, Khanna R, Ng SC, Panés J, van Assche G, Liu Z, Hart A, Levesque BG, D' Haens G; World Gastroenterology Organization, International Organisation for Inflammatory Bowel Diseases IOIBD, European Society of Coloproctology and Robarts Clinical Trials; World Gastroenterology Organization International Organisation for Inflammatory Bowel Diseases IOIBD European Society of Coloproctology and Robarts Clinical Trials. A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease. *Gut* 2014; **63**: 1381-1392 [PMID: 24951257 DOI: 10.1136/gutjnl-2013-306709]

3 **Amiot A**, Setakhr V, Seksik P, Allez M, Treton X, De Vos M, Laharie D, Colombel JF, Abitbol V, Reimund JM, Moreau J, Veyrac M, Flourié B, Cosnes J, Lemann M, Bouhnik Y. Long-term outcome of enterocutaneous fistula in patients with Crohn's disease treated with anti-TNF therapy: a cohort study from the GETAID. *Am J Gastroenterol* 2014; **109**: 1443-1449 [PMID: 25091063 DOI: 10.1038/ajg.2014.183]

4 **Bor R**, Farkas K, Bálint A, Szucs M, Ábrahám S, Baradnay G, Wittmann T, Szepes Z, Nagy F, Molnár T. Efficacy of combined anti-TNF-alpha and surgical therapy in perianal and enterocutaneous fistulizing Crohn's disease--clinical observations from a tertiary Eastern European center. *Scand J Gastroenterol* 2015; **50**: 182-187 [PMID: 25384713 DOI: 10.3109/00365521.2014.936033]

5 **Karmiris K**, Bielen D, Vanbeckevoort D, Vermeire S, Coremans G, Rutgeerts P, Van Assche G. Long-term monitoring of infliximab therapy for perianal fistulizing Crohn's disease by using magnetic resonance imaging. *Clin Gastroenterol Hepatol* 2011; **9**: 130-136 [PMID: 21056696 DOI: 10.1016/j.cgh.2010.10.022]

6 **Bouguen G**, Siproudhis L, Bretagne JF, Bigard MA, Peyrin-Biroulet L. Nonfistulizing perianal Crohn's disease: clinical features, epidemiology, and treatment. *Inflamm Bowel Dis* 2010; **16**: 1431-1442 [PMID: 20310013 DOI: 10.1002/ibd.21261]

7 **Tozer P**, Ng SC, Siddiqui MR, Plamondon S, Burling D, Gupta A, Swatton A, Tripoli S, Vaizey CJ, Kamm MA, Phillips R, Hart

A. Long-term MRI-guided combined anti-TNF-α and thiopurine therapy for Crohn's perianal fistulas. *Inflamm Bowel Dis* 2012; **18**: 1825-1834 [PMID: 22223472 DOI: 10.1002/ibd.21940]

8 **Ng SC**, Plamondon S, Gupta A, Burling D, Swatton A, Vaizey CJ, Kamm MA. Prospective evaluation of anti-tumor necrosis factor therapy guided by magnetic resonance imaging for Crohn's perineal fistulas. *Am J Gastroenterol* 2009; **104**: 2973-2986 [PMID: 19755971 DOI: 10.1038/ajg.2009.509]

9 **Tougeron D**, Savoye G, Savoye-Collet C, Koning E, Michot F, Lerebours E. Predicting factors of fistula healing and clinical remission after infliximab-based combined therapy for perianal fistulizing Crohn's disease. *Dig Dis Sci* 2009; **54**: 1746-1752 [PMID: 19003531 DOI: 10.1007/s10620-008-0545-y]

10 **Sands BE**, Anderson FH, Bernstein CN, Chey WY, Feagan BG, Fedorak RN, Kamm MA, Korzenik JR, Lashner BA, Onken JE, Rachmilewitz D, Rutgeerts P, Wild G, Wolf DC, Marsters PA, Travers SB, Blank MA, van Deventer SJ. Infliximab maintenance therapy for fistulizing Crohn's disease. *N Engl J Med* 2004; **350**: 876-885 [PMID: 14985485 DOI: 10.1056/NEJMoa030815]

11 **Thomassin L**, Armengol-Debeir L, Charpentier C, Bridoux V, Koning E, Savoye G, Savoye-Collet C. Magnetic resonance imaging may predict deep remission in patients with perianal fistulizing Crohn's disease. *World J Gastroenterol* 2017; **23**: 4285-4292 [PMID: 28694669 DOI: 10.3748/wjg.v23.i23.4285]

12 **Savoye-Collet C**, Savoye G, Koning E, Dacher JN, Lerebours E. Fistulizing perianal Crohn's disease: contrast-enhanced magnetic resonance imaging assessment at 1 year on maintenance anti-TNF-alpha therapy. *Inflamm Bowel Dis* 2011; **17**: 1751-1758 [PMID: 21744430 DOI: 10.1002/ibd.21568]

13 **Kotze PG**, Albuquerque IC, da Luz Moreira A, Tonini WB, Olandoski M, Coy CS. Perianal complete remission with combined therapy (seton placement and anti-TNF agents) in Crohn's disease: a Brazilian multicenter observational study. *Arq Gastroenterol* 2014; **51**: 284-289 [PMID: 25591155 DOI: 10.1590/S0004-28032014000400004]

14 **Castaño-Milla C**, Chaparro M, Saro C, Barreiro-de Acosta M, García-Albert AM, Bujanda L, Martín-Arranz MD, Carpio D, Muñoz F, Manceñido N, García-Planella E, Piqueras M, Calvet X, Cabriada JL, Botella B, Bermejo F, Gisbert JP. Effectiveness of adalimumab in perianal fistulas in crohn's disease patients naive to anti-TNF therapy. *J Clin Gastroenterol* 2015; **49**: 34-40 [PMID: 25485513 DOI: 10.1097/MCG.0000000000000169]

15 **Fortea-Ormaechea JI**, González-Lama Y, Casis B, Chaparro M, López Serrano P, Van Domselaar M, Bermejo F, Pajares R, Ponferrada A, Vera MI, Martínez Montiel P, Gisbert JP, Pérez-Calle JL, López San Román A, Abreu L, Menchén LA, Marín-Jiménez I. Adalimumab is effective in long-term real life clinical practice in both luminal and perianal Crohn's disease. The Madrid experience. *Gastroenterol Hepatol* 2011; **34**: 443-448 [PMID: 21724297 DOI: 10.1016/j.gastrohep.2011.04.001]

16 **Colombel JF**, Sandborn WJ, Rutgeerts P, Enns R, Hanauer SB, Panaccione R, Schreiber S, Byczkowski D, Li J, Kent JD, Pollack PF. Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. *Gastroenterology* 2007; **132**: 52-65 [PMID: 17241859 DOI: 10.1053/j.gastro.2006.11.041]

17 **Colombel JF**, Schwartz DA, Sandborn WJ, Kamm MA, D'Haens G, Rutgeerts P, Enns R, Panaccione R, Schreiber S, Li J, Kent JD, Lomax KG, Pollack PF. Adalimumab for the treatment of fistulas in patients with Crohn's disease. *Gut* 2009; **58**: 940-948 [PMID: 19201775 DOI: 10.1136/gut.2008.159251]

18 **Schreiber S**, Lawrance IC, Thomsen OØ, Hanauer SB, Bloomfield R, Sandborn WJ. Randomised clinical trial: certolizumab pegol for fistulas in Crohn's disease - subgroup results from a placebo-controlled study. *Aliment Pharmacol Ther* 2011; **33**: 185-193 [PMID: 21083671 DOI: 10.1111/j.1365-2036.2010.04509.x]

19 **Papamichael K**, Chachu KA, Vajravelu RK, Vaughn BP, Ni J, Osterman MT, Cheifetz AS. Improved Long-term Outcomes of Patients With Inflammatory Bowel Disease Receiving Proactive Compared With Reactive Monitoring of Serum Concentrations of Infliximab. *Clin Gastroenterol Hepatol* 2017; **pii**: S1542-3565(17)30385-3 [PMID: 28365486 DOI: 10.1016/j.cgh.2017.03.031]

20 **Van Stappen T**, Bollen L, Vande Casteele N, Papamichael K, Van Assche G, Ferrante M, Vermeire S, Gils A. Rapid Test for Infliximab Drug Concentration Allows Immediate Dose Adaptation. *Clin Transl Gastroenterol* 2016; **7**: e206 [PMID: 27929524 DOI: 10.1038/ctg.2016.62]

21 **Papamichael K**, Van Stappen T, Vande Casteele N, Gils A, Billiet T, Tops S, Claes K, Van Assche G, Rutgeerts P, Vermeire S, Ferrante M. Infliximab Concentration Thresholds During Induction Therapy Are Associated With Short-term Mucosal Healing in Patients With Ulcerative Colitis. *Clin Gastroenterol Hepatol* 2016; **14**: 543-549 [PMID: 26681486 DOI: 10.1016/j.cgh.2015.11.014]

22 **Ungar B**, Levy I, Yavne Y, Yavzori M, Picard O, Fudim E, Loebstein R, Chowers Y, Eliakim R, Kopylov U, Ben-Horin S. Optimizing Anti-TNF-α Therapy: Serum Levels of Infliximab and Adalimumab Are Associated With Mucosal Healing in Patients With Inflammatory Bowel Diseases. *Clin Gastroenterol Hepatol* 2016; **14**: 550-557.e2 [PMID: 26538204 DOI: 10.1016/j.cgh.2015.10.025]

23 **Ward MG**, Warner B, Unsworth N, Chuah SW, Brownclarke C, Shieh S, Parkes M, Sanderson JD, Arkir Z, Reynolds J, Gibson PR, Irving PM. Infliximab and adalimumab drug levels in Crohn's disease: contrasting associations with disease activity and influencing factors. *Aliment Pharmacol Ther* 2017; **46**: 150-161 [PMID: 28481014 DOI: 10.1111/apt.14124]

24 **Roblin X**, Marotte H, Leclerc M, Del Tedesco E, Phelip JM, Peyrin-Biroulet L, Paul S. Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel disease. *J Crohns Colitis* 2015; **9**: 525-531 [PMID: 25895875 DOI: 10.1093/ecco-jcc/jjv061]

25 **Paul S**, Del Tedesco E, Marotte H, Rinaudo-Gaujous M, Moreau A, Phelip JM, Genin C, Peyrin-Biroulet L, Roblin X. Therapeutic drug monitoring of infliximab and mucosal healing in inflammatory bowel disease: a prospective study. *Inflamm Bowel Dis* 2013; **19**: 2568-2576 [PMID: 24013361 DOI: 10.1097/MIB.0b013e3182a77b41]

26 **Yarur AJ**, Kanagala V, Stein DJ, Czul F, Quintero MA, Agrawal D, Patel A, Best K, Fox C, Idstein K, Abreu MT. Higher infliximab trough levels are associated with perianal fistula healing in patients with Crohn's disease. *Aliment Pharmacol Ther* 2017; **45**: 933-940 [PMID: 28211593 DOI: 10.1111/apt.13970]

27 **Davidov Y**, Ungar B, Bar-Yoseph H, Carter D, Haj-Natour O, Yavzori M, Chowers Y, Eliakim R, Ben-Horin S, Kopylov U. Association of Induction Infliximab Levels With Clinical Response in Perianal Crohn's Disease. *J Crohns Colitis* 2017; **11**: 549-555 [PMID: 28453755 DOI: 10.1093/ecco-jcc/jjw182]

P- Reviewer: Lakatos PL, Negreanu N, Walter F **S- Editor**: Ma YJ
L- Editor: A **E- Editor**: Zhang FF

Published by **Baishideng Publishing Group Inc**
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Telephone: +1-925-223-8242
Fax: +1-925-223-8243
E-mail: bpgoffice@wjgnet.com
Help Desk: http://www.f6publishing.com/helpdesk
http://www.wjgnet.com

ISSN 1007-9327